ERBB2 and gastroesophageal junction adenocarcinoma: DESTINY-Gastric01, a randomized phase II trial in Japan and South Korea, enrolled patients with HER2-positive advanced gastric or GEJ adenocarcinoma who had received ≥2 prior lines of therapy, including trastuzumab.